DURHAM — Alcami Corporation, a contract development and manufacturing organization with a focus on pharmaceutical and biologic companies, has sold its preclinical and early stage active pharmaceutical ingredient (API) facility in Weert, Netherlands.
The buyers are MercachemSyncom, a leading mid-sized European integrated drug-discovery and development contract research organization.
The Durham-based firm, which has a second office in Wilmington and has some 900 employees, declined to disclose the terms.
“This transaction represents another key step in the strategic development of Alcami’s service delivery platform, focusing investments across our network toward high-growth market segments,” said Alcami Chief Commercial Officer Chad Telgenhof, in a statement.
“Additionally, our European sales and business development team will remain with our organization and continue to serve a strong and growing pipeline of Europe-based clients who are partnered with Alcami in the development and commercialization of their products.”
Alcami provides contract drug and biologics development and manufacturing services, including formulation development, analytical chemistry, API, solid dose and parenteral drug manufacturing for clinical and commercial markets.
In December, the company announced a 6,000-square-foot expansion at its facility in Charleston, South Carolina. The firm said it will “significantly augment” the capacity of Alcami’s sterile drug product development and manufacturing operations.
The $17 million investment is expected to create 30 new jobs in Charleston and be completed in 2021.